Data Sheet (Cat.No.T7130)

TargetMol

Navarixin

Chemical Properties



CAS No. : 473727-83-2

Formula: C21H23N3O5

Molecular Weight: 397.42

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Navarixin (MK-7123)(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia.
Targets(IC50)	CXCR
In vitro	Navarixin is a potent, allosteric antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, and 0.08 nM for mouse, rat, and cynomolgus monkey CXCR2, respectively [1].

Solubility Information

Solubility	DMSO: 60 mg/mL (150.97 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.03 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5162 mL	12.5811 mL	25.1623 mL
5 mM	0.5032 mL	2.5162 mL	5.0325 mL
10 mM	0.2516 mL	1.2581 mL	2.5162 mL
50 mM	0.0503 mL	0.2516 mL	0.5032 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Gonsiorek W , Fan X , Hesk D , et al. Pharmacological Characterization of Sch527123, a Potent Allosteric CXCR1/CXCR2 Antagonist[J]. Journal of Pharmacology and Experimental Therapeutics, 2007, 322(2):477-485.
Luo Q, Dong Z, Xie W, et al.Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy.Cell Reports.2023, 42(5).
Holz O, Khalilieh S, Ludwig-Sengpiel A,et al.SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects[J].Eur Respir J. 2010 Mar;35(3):564-70.